In an unexpected development for UCB, the long-awaited results from the phase III ARCH study of its osteoporosis drug Romosozumab (trade name Evenity) – co-developed with Amgen – threw up serious side effects, sending the share down by c.18% (22 May 2017), the company’s worst single day performance in the last three decades. While the drug was able to meet both its primary and secondary endpoints – significantly reducing the incidence of new vertebral fractures over 24 ....